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Introduction
Gestational Trophoblastic disease is a continuum, 
which covers a wide range of states from benign molar 
pregnancy to Gestational Trophoblastic Neoplasia 
(GTN) (Aminimoghaddam et al., 2018; Rachdi et al., 
2019). Molar pregnancy is divided into three categories; 
complete, partial, and invasive mole, and malignant 
form (Hurteau, 2003). Malignant form is a rare disease, 
which is divided into three categories; choriocarcinoma, 
Placental Site Trophoblastic Tumor (PSTT), Epithelioid 
Trophoblastic Tumor (Aminimoghaddam et al., 2016). 
All three types of benign molar pregnancy can be 
detected using histopathology, karyotype, and gross 
appearance of placenta. Hysterectomy should be 
used to detect invasive mole (Aminimoghaddam and 
Maghsoudnia, 2017). To define the characteristics of each 
type of molar pregnancies, trophoblastic proliferation 
should be addressed. In a complete mole, trophoblastic 
proliferation is excessive, while, a few trophoblastic tissue 
is detected in partial mole (Seckl et al., 2010). In invasive 
mole, trophoblastic invasion into the myometrium 
followed by villous formation are detected (Milani, 
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2017). Choriocarcinoma is the most malignant form of 
GTN, which has a high tendency to develop metastasis 
(Berkowitz and Goldstein, 1996). Pathology report 
shows bleeding and necrosis without villous formation 
in placental tissue. The GTN can be detected in different 
situations; after evacuation of molar pregnancy (with 
50% occurrence rate), after term pregnancy (with 25% 
occurrence rate), and after ectopic pregnancy abortion 
(with 25% occurrence rate) (Altieri et al., 2003). 
Regarding predisposing factors, old women (who are 
in advanced ages) or women who had previous molar 
pregnancies are highly susceptive to have complete 
molar pregnancy (Altieri et al., 2003). High-risk mole, 
which originated mainly from complete moles, is the 
most important factor that causes GTN. High-risk mole 
is diagnosed if any of the following conditions meet; if 
ΒHCG is more than or equal to 100,000, if theca lutein 
cyst size is bigger than or equal to 6 cm, if age is more 
than or equal to 40 years, and if uterine size is larger than 
expected gestational age (Aminimoghaddam et al., 2018; 
Berkowitz and Goldstein, 2009). 
Regarding diagnosing of GTN, literature shows that it 
can be diagnosed if any of the following conditions meet: 
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if βHCG is rises for 3 successive weeks after evacuation 
of molar pregnancy, if ΒHCG decreases less than 10% 
after 4 weeks of molar pregnancy evacuation (plateau), if 
choriocarcinoma had been detected in histology, if ΒHCG 
level can be measured after 6 months of evacuation of 
molar pregnancy (Schorge et al., 2000). Diagnosis is 
followed by anatomical staging (recommended based 
on FIGO (Oncology, 2009)) and scoring (recommended 
by WHO (Seckl et al., 2010)), which paves the way 
of treatment with single agent or multiple agents’ 
chemotherapy (Aminimoghaddam et al., 2018; Yarandi 
et al., 2016).
The GTN can be reduced by taking methotrexate or 
actinomycin-D, as the prophylactic treatments, before or 
within the suction curettage process. Actinomycin –D is 
generally used in bolus doses, while MTX can be used in 
single dose or in combination with leucovorin. These two 
drugs are generally used in observational studies. 
In summary, molar pregnancy is prevalent in the middle 
eastern countries (Gül et al., 1997). This proliferation, 
which engenders in having multiple patients with GTN, 
enables the authors to investigate the effect of using 
MTX- leucovorin as the prophylactic drugs. Moreover, 
this study addresses the toxicity of using methotrexate. 
Materials and Methods
The present analytical, case-control retrospective study 
was performed in patients with high-risk moles referred 
to Akbarabadi and Firoozgar teaching hospitals, affiliated 
to Iran University of Medical Sciences (IUMS) in Tehran, 
during 2003-2013. 102 female patients were included in 
this study, which had at least one of the following inclusion 
criteria (Wolfberg et al., 2006). 
1. Uterine size larger than the gestation age
2. βHCG more than 100,000 (IU/ml)
3. Ovarian theca lutein cyst larger than 6cm
4. Age > 40 years
It should be noted that by having only one of these 
conditions, the patient is counted as a high-risk mole 
patient. Five groups of patients were not included in this 
study, which were:
1. Poor physical conditions
2. Abnormal liver function test
3. Abnormal CBC and renal function test
4. Lack of self-interest to take prophylactic 
chemotherapy
5. Incomplete records
Study protocol was approved by the Institutional 
Review Board (IRB) at Iran University of Medical 
Sciences (approval number: IR.IUMS.FMD.REC 
1393.1536). In this study, all the principles of the 
Declaration of Helsinki (ethics in medical research on 
humans) and Code of Ethics adopted by the Ministry of 
Health at all stages of Association were followed. The data 
was collected from patients records and no extra expenses 
were imposed on the patients (Ghaoomeh et al., 2016).
The patients were divided into two groups, randomly: 
Group I) those receiving prophylactic chemotherapy 
(Methotrexate 1mg/kg in the odd days (1,3,5,7) and 
leucovorin 0.1 mg/kg (IM) in the even days (2,4,6,8); 
and Group II) those who did not receive it. Patients’ 
demographic data included age, number of pregnancies, 
weight, vaginal bleeding duration, improvement period, 
βHCG serum level before and after intervention, liver 
function tests levels, and finally diagnosis of GTN were 
recorded. The data were entered into a previously designed 
checklist. 
GTN was defined considering the presence of one 
of the following cases (Aminimoghaddam et al., 2018; 
Seckl et al., 2010):
1. Increase in the βHCG to 10% in three consecutive 
periods
2. Reduction of βHCG to 10% following four times 
measurement (Plateau)
3. Evidence of choriocarcinoma in the pathology
4. Having a high βHCG level in 6 months after suction 
curettage.
We measured the liver function test level four times per 
cycle, and we measured it at the same day that the patient 
received the methotrexate. In females with abnormal 
liver function tests (two times of the liver enzyme), the 
drug use was discontinued, and was resumed following 
normalization of the patient’s laboratory data. We followed 
them up for a year by taking βHCG level each month.
 
Statistical analysis
The data were collected and the SPSS Software 16 
was used . The mean and standard deviation (SD) were 
calculated, since the data followed normal distribution. 
Independent t-test was used to demonstrate GTN of the 
two different groups. Moreover, in order to compare the 
qualitative variables, the Chi²- square test was used. A 
P-value<0.05 was considered as significant. 
Results
One hundred two patients with a mean age of 
27.7±7.37 were enrolled in the study. The youngest patient 
was 15 years old, while the eldest was 48years. Half of 
the patients (51; 50%) received MTX as the prophylactic 
drug, while the other half did not receive it. Liver function 
test of each patient is measured the same day that (s)he 
received the methotrexate four times per cycle. Finally, 
23 patients (22.5 %) were developed with GTN, while 79 
patients (77.5 %) were not.  
Among the patients with GTN, 12 (52.17%) had an 
increase of βHCG, 11 patients (47.82%) showed less than 
10% decrease in βHCG (plateau). The results show that 
the first two inclusion criteria were seen mostly among 
the patients, and the last two were not met. Also, in the 
inclusion criteria, the first one was the most prevalent.
There was a significant difference between the number 
of patients with GTN in the recipient MTX group (7 
women ~13.7 %) and the number of patients with GTN 
in the non-recipient MTX group (16 women ~ 31.4 %) 
with p-value =0.03, (Figure 1). There was a significant 
difference in average of the month to normalization of 
βHCG (spontaneous remission) between MTX recipient 
patients (2.5±1.33) and non-recipient MTX patients 
(3.2±1.21) (P<0.001). While, there was not any significant 
difference with regards to age (P=0.79), parity, gravidity 
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(with the history of molar pregnancy evacuation) who 
are not coming back to have a follow up (Elza Maria 
Hartmann Uberti et al., 2009; Wang et al., 2017). In Latin 
America, about 44% of the patients won’t be followed up 
(Uberti et al., 2009). The country this study performed is a 
developing country, which attracts multiple international 
work force (immigrant). These kinds of patients are not 
interested to have a follow up due to the costs burden 
associated with it. So, this area is a bed stream for having 
such studies. 
Aminimoghaddam et al., (2017) concluded that the 
majority of patients affected by invasive mole had previous 
high-risk molar pregnancy. However, actinomycin D is a 
scientific substitute for MTX. A study in 2009, showed 
that there is no significant difference between the two 
drugs (Uberti et al., 2009). Uberti et al., (2009) had 
another approach and prescribed actinomycin D in patients 
with high-risk mole. Results showed that prophylactic 
chemotherapy could lower the GTN rate, as well as 
treatment costs, though the usage of this drug has no 
significant impact on the morbidity and diseases intensity 
(Vargas et al., 2014). This reduction was quantified in two 
studies; Uberti et al. showed that the use of actinomycin D 
prior to suction curettage reduces the GTN rate up to 46% 
(Uberti et al., 2006), while Cunha et al., (2009) found this 
reduction rate to be 76% (Uberti et al., 2009). However, 
this study practiced using MTX since actinomycin D was 
not available in the country this study performed. 
From a different perspective, some scholars proved 
the effectiveness of using leucovorin beside MTX 
(Aminimoghaddam et al., 2018; Wang et al., 2017; Yarandi 
et al., 2016), while this study had a focus on the level of 
toxicity, which makes it unique. A rise in liver enzyme 
was seen as a side effect of MTX, which engendered 
terminating MTX. This termination made the level of 
liver enzyme normal again. It should be said that this 
treatment was continued for a full treatment period as it 
was mentioned. 
Future research
It is suggested to evaluate the risk of GTN by using 
prophylactic chemotherapy by conducting an RCT study. 
Additionally, drug resistance, toxicity, overall survival and 
reproductive outcome should be clarified in this study.
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